Dashboard
Manage Tickers

SNDX


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
Incyte, Syndax Report Publication Of Data ...
09/18/2024 21:20:03

syndax-pharmaceuticals-partnered-with-foundation-medicine-to-develop-a-companion-diagnostic-for-the-identification-of-acute-myeloid-leukemia-patients-harboring-an-npm1-mutation
Syndax Pharmaceuticals Partnered With Foun...
09/04/2024 11:12:41

citigroup-maintains-buy-on-syndax-pharmaceuticals-raises-price-target-to-34
Citigroup Maintains Buy on Syndax Pharmace...
08/16/2024 13:01:52

Citigroup analyst Yigal Nochomovitz maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and raises the price target fr...

hc-wainwright--co-maintains-buy-on-syndax-pharmaceuticals-raises-price-target-to-45
HC Wainwright & Co. Maintains Buy on Synda...
08/15/2024 17:26:30

HC Wainwright & Co. analyst Edward White maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and raises the price ...

b-of-a-securities-maintains-buy-on-syndax-pharmaceuticals-raises-price-target-to-31
B of A Securities Maintains Buy on Syndax ...
08/15/2024 17:22:54

B of A Securities analyst Jason Zemansky maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and raises the price targ...

fda-approves-incytesyndax-partnered-drug-for-chronic-graft-versus-host-disease-a-post-transplant-complication
FDA Approves Incyte/Syndax Partnered Drug ...
08/15/2024 14:11:20

The FDA has approved Incyte and Syndax Pharmaceuticals' Niktimvo for chronic graft-versus-host disease in patients after at...

barclays-maintains-overweight-on-syndax-pharmaceuticals-raises-price-target-to-33
Barclays Maintains Overweight on Syndax Ph...
08/15/2024 13:57:21

Barclays analyst Peter Lawson maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Overweight and raises the price target f...

Core News & Articles
Incyte, Syndax Secure FDA Approval For Nik...
08/14/2024 21:55:48

FDA has approved Niktimvo (axatilimab-csfr), an anti-CSF-1R antibody, for the treatment of chronic graft-versus-host disease (G...

syndax-pharmaceuticals-announced-that-data-from-phase-2-portion-of-the-augment-101-trial-of-revumenib-in-adult-and-pediatric-patients-with-relapsedrefractory-kmt2a-rearranged-acute-myeloid-leukemia-and-acute-lymphoid-leukemia-have-been-published-in-the-journal-of-clinical-oncology
Syndax Pharmaceuticals Announced That Data...
08/12/2024 11:09:10

jp-morgan-maintains-overweight-on-syndax-pharmaceuticals-lowers-price-target-to-33
JP Morgan Maintains Overweight on Syndax P...
08/06/2024 16:25:14

JP Morgan analyst Anupam Rama maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Overweight and lowers the price target f...

hc-wainwright--co-reiterates-buy-on-syndax-pharmaceuticals-maintains-41-price-target
HC Wainwright & Co. Reiterates Buy on Synd...
08/02/2024 12:04:57

HC Wainwright & Co. analyst Edward White reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $41 pr...

syndax-pharmaceuticals-q2-2024-gaap-eps-080-beats-093-estimate-sales-3500m
Syndax Pharmaceuticals Q2 2024 GAAP EPS $(...
08/01/2024 20:36:03

Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate o...

hc-wainwright--co-reiterates-buy-on-syndax-pharmaceuticals-maintains-41-price-target
HC Wainwright & Co. Reiterates Buy on Synd...
07/29/2024 17:45:42

HC Wainwright & Co. analyst Edward White reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $41 pr...

fda-extends-review-period-for-syndax-pharmaceuticals-leukemia-drug-revumenib
FDA Extends Review Period for Syndax Pharm...
07/29/2024 11:03:07

Syndax Pharmaceuticals (NASDAQ:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer th...

jefferies-initiates-coverage-on-syndax-pharmaceuticals-with-buy-rating-announces-price-target-of-37
Jefferies Initiates Coverage On Syndax Pha...
06/28/2024 12:49:09

Jefferies analyst Kelly Shi initiates coverage on Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy rating and announces Price...

stifel-maintains-buy-on-syndax-pharmaceuticals-raises-price-target-to-42
Stifel Maintains Buy on Syndax Pharmaceuti...
06/26/2024 14:07:41

Stifel analyst Bradley Canino maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and raises the price target from $40...

hc-wainwright--co-reiterates-buy-on-syndax-pharmaceuticals-maintains-41-price-target
HC Wainwright & Co. Reiterates Buy on Synd...
06/17/2024 10:34:40

HC Wainwright & Co. analyst Edward White reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $41 pr...

syndax-pharmaceuticals-discloses-updated-data-from-multiple-combination-trials-of-revumenib-the-companys-potent-small-molecule-menin-inhibitor-in-patients-with-acute-leukemias
Syndax Pharmaceuticals Discloses Updated D...
06/14/2024 11:09:01

- Data continue to support revumenib's potential to enhance current standard of care agents - - 96% CRc (23 of 24 pts) obs...

hc-wainwright--co-reiterates-buy-on-syndax-pharmaceuticals-maintains-41-price-target
HC Wainwright & Co. Reiterates Buy on Synd...
06/06/2024 14:12:27

HC Wainwright & Co. analyst Edward White reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $41 pr...

syndaxs-revumenib-to-enter-phase-1b-for-metastatic-colorectal-cancer-after-idmc-endorsement
Syndax's Revumenib To Enter Phase 1b For M...
06/06/2024 11:08:18

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION